ABIO News and Press, ARCA biopharma Inc. From 05/02/22

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company a...

ARCA biopharma (NASDAQ:ABIO) on Monday established a special committee of its board of directors to evaluate strategic options for the biopharmaceutical company. ABIO did not specify what kind of options the committee would evaluate. ABIO stock +4.7% to $2.43 in aftermarket trading. The forma...

WESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that its Board of Directors has establ...

Gainers: ORIC Pharmaceuticals (ORIC) +14%. Unity Biotechnology (UBX) +13%. Applied Therapeutics (APLT) +11%. Genetron (GTH) +11%. Clarus Therapeutics (CRXT) +8%. Losers: SELLAS Life Sciences SLS -39%. Pulse Biosciences (PLSE) -22%. Spero Therapeutics SPRO&#x...

Arca Biopharma (NASDAQ:ABIO) is trading ~28% lower in the post-market Thursday after the clinical-stage biotech announced that its experimental COVID-19 therapy rNAPc2 failed to meet the primary endpoint with statistical significance in a Phase 2b trial. The 160-patient internationa...

For the entire cohort of COVID-19 hospitalized patients, the pooled lower and higher rNAPc2 dose groups demonstrated a reduction compared to baseline in D-dimer levels of 16.8% versus 11.2% for standard of care heparin which was not statistically significant and consequently did not a...

ARCA biopharma press release (NASDAQ:ABIO): FY GAAP EPS of -$1.39. FY Cash and cash equivalents of $53.4M For further details see: ARCA biopharma GAAP EPS of -$1.39

WESTMINSTER, Colo., March 14, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2021 financial results and provided a c...

Clinically important bradycardia is common in heart failure (HF) patients with persistent or paroxysmal atrial fibrillation (AF) In a Phase 2B clinical trial, the prevalence of clinically important bradycardia was statistically significantly lower for Gencaro TM compared to metopr...

Penny Stocks To Buy For Under $5; Are They Worth The Risk? There are so many traders in the stock market today searching for top penny stocks to buy. These high-risk assets have been a source for some of the biggest winning trades over the last few years. I’m not only talking abo...